Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

ESLA

Estrella Immunopharma, Inc.

Tremor tracks 1 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

  • A key executive is leavingSince Oct 29, 2026+13.7

Trials

  • ESLAEstrella Immunopharma, Inc.
    14Calm

    T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

    Signing up patientsPhase 1/227 patientsMain results: Jul 31, 2027

Key executives leaving

From the last 12 months of the company's SEC reports.

  • Oct 29, 2026

    “Effective October 25, 2026, Cheng Liu, Ph.D., ceased to serve as Chief Executive Officer and was appointed Chief Scientific Officer;”

    Read the filing ↗

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 0 purchases

No insider sales or purchases in the last 6 months.

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

  • A key executive is leavingNews report (8-K)Oct 29, 2026
  • Warning about being removed from the stock exchangeNews report (8-K)Sep 8, 2026
  • Warning about being removed from the stock exchangeNews report (8-K)Aug 21, 2026
  • Quarterly reportQuarterly report (10-Q)Aug 13, 2026
  • News reportNews report (8-K)Jun 30, 2026

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.
Quarterly reportQuarterly report (10-Q)
May 18, 2026